文献速递乳腺癌放疗

荷兰COVID-19疫情期间乳腺癌超大分割放疗方案的实施情况

Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-14

本研究基于荷兰乳腺癌审计-放疗与荷兰癌症登记数据,纳入2020年1月1日至2021年12月31日接受放疗的原发浸润性乳腺癌或导管原位癌女性,分析不同放疗方案的使用趋势及符合FAST和FAST-Forward试验标准的肿瘤接受五次分割放疗的可能性。结果显示,疫情初期五次分割放疗使用率快速上升,2020年3月仅3%,2020年4月达19%,2021年12月增至26%;部分乳腺照射和学术放疗机构与接受五次分割放疗显著相关。

要点

  • 2020年3月仅3%的肿瘤接受五次分割放疗,2020年4月升至19%,2021年12月增至26%。
  • 部分乳腺照射较全乳腺照射与接受五次分割放疗显著相关。
  • 学术放疗机构较独立机构与接受五次分割放疗显著相关。

核心结论

  • COVID-19疫情开始与超大分割放疗方案的早期使用相关,试验发表后及主要在国家放疗学会推荐后实施进一步增加,但并非所有符合FAST或FAST-Forward试验入选标准的患者均使用这些方案。

研究设计与样本

  • 基于荷兰乳腺癌审计-放疗与荷兰癌症登记数据的分析,纳入2020年1月1日至2021年12月31日接受放疗的原发浸润性乳腺癌或导管原位癌女性,共获得9,392个肿瘤的详细放疗信息,采用逻辑回归分析接受五次分割放疗的可能性。

主要发现

  • 2020年3月仅3%的肿瘤接受五次分割放疗,2020年4月疫情开始后不久升至19%,2021年12月增至26%。
  • 部分乳腺照射较全乳腺照射与接受五次分割放疗显著相关。
  • 学术放疗机构较独立机构与接受五次分割放疗显著相关。

关键数值与推荐

  • 五次分割放疗的剂量为5.2或5.7 Gy每次。
  • 分析接受五次分割放疗可能性的对象为符合FAST和FAST-Forward试验标准的肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The COVID-19 pandemic resulted in an accelerated recommendation to use five-fraction radiotherapy schedules, according to the FAST- and FAST-Forward trial. In this study, trends in the use of different radiotherapy schedules in the Netherlands were studied, as well as the likelihood of receiving five fractions. MATERIALS AND METHODS: Data from the NABON Breast Cancer Audit-Radiotherapy and Netherlands Cancer Registry was used. Women receiving radiotherapy for their primary invasive breast cancer or DCIS between 01-01-2020 and 31-12-2021 were included. Logistic regression was used to investigate the association between patient-, tumour-, treatment-, and radiotherapy institution-related characteristics and the likelihood of receiving five fractions in tumours meeting the FAST and FAST-Forward criteria. RESULTS: Detailed information about radiotherapy treatment was available for 9,392 tumours. Shortly after the start of the COVID-19 pandemic, i.e. April 2020, 19% of the tumours being treated with radiotherapy received five fractions of 5.2 or 5.7 Gray (Gy). While only 3% of the tumours received five fractions in March 2020. The usage of five fractions increased to 26% in December 2021. Partial breast irradiation, compared to whole breast irradiation, was significantly associated with the administration of five fractions, as well as radiotherapy delivered in an academic radiotherapy institution compared to an independent institution. CONCLUSION: The start of the COVID-19 pandemic was associated with the early use of ultra-hypofractionated radiotherapy schedules. After publication of the trials, and mainly after the recommendation by the national radiotherapy society, the implementation further increased. These schedules were not yet used in all patients meeting the eligibility criteria for the FAST- or FAST-Forward trial.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eijkelboom AH, Stam MR, van den Bongard DHJG, et al. Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands. Clin Transl Radiat Oncol. 2024. PMID: 38979479. doi:10.1016/j.ctro.2024.100807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。